Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.58 |
| ▸ | AR | P10275 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SHBG | P04278 | 1/20 | 0.48 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544872 | 1.00 | PGR (0.67) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918110 | 1.00 | PGR (0.67) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL12473404 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918130 | 0.88 | PGR (0.79) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL15354859 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL2168575 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL13918127 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| SCHEMBL2168200 | 0.88 | PGR (0.69) | PGRNR3C1ARCYP2C19LMNA | |
| Demegestone SCHEMBL146550 | 0.87 | PGR (0.78) | PGRNR3C1ARCYP2C19LMNA | |
| Demegestone SCHEMBL6851326 | 0.87 | PGR (0.78) | PGRNR3C1ARCYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774933-B1 | ULIPRISTAL ACETATE PREPARATION METHOD AND INTERMEDIATE THEREOF | UTOPHARM (SHANGHAI) CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9163058-B2 | Method for preparing ulipristal acetate and key intermediate thereof | UTOPHARM (SHANGHAI) CO., LTD (CN) | 2015-10-20 | — | — | US | disclosed |
| US-9163058-B2 | Method for preparing ulipristal acetate and key intermediate thereof | UTOPHARM (SHANGHAI) CO., LTD (CN) | 2015-10-20 | — | — | US | disclosed |
| US-20140296510-A1 | Method for preparing ulipristal acetate and key intermediate thereof | Changzhou Siyao Pharm Co., Ltd. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296510-A1 | Method for preparing ulipristal acetate and key intermediate thereof | Changzhou Siyao Pharm Co., Ltd. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2774933-A1 | ULIPRISTAL ACETATE PREPARATION METHOD AND INTERMEDIATE THEREOF | Utopharm (Shanghai) Co., Ltd (CN) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296510-A1 | Method for preparing ulipristal acetate and key intermediate thereof | KIT, UGT1A4, CYP4A11 | PGR 424/4885NR3C1 134/4885AR 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.